High-resolution melting effectively pre-screens for TP53 mutations before direct sequencing in patients with diffuse glioma

[1]  R. Backofen,et al.  A pan-cancer analysis of synonymous mutations , 2019, Nature Communications.

[2]  H. Takeshima,et al.  Impact of PCR-based molecular analysis in daily diagnosis for the patient with gliomas , 2018, Brain Tumor Pathology.

[3]  D. Carpizo,et al.  Zinc Metallochaperones as Mutant p53 Reactivators: A New Paradigm in Cancer Therapeutics , 2018, Cancers.

[4]  Pieter Wesseling,et al.  cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant , 2018, Acta Neuropathologica.

[5]  E. Cambruzzi.  Medulloblastoma, WNT-activated/SHH-activated: clinical impact of molecular analysis and histogenetic evaluation , 2018, Child's Nervous System.

[6]  D. Louis,et al.  cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC) , 2018, Acta Neuropathologica.

[7]  Arnold J Levine,et al.  Why are there hotspot mutations in the TP53 gene in human cancers? , 2017, Cell Death and Differentiation.

[8]  P. Brown,et al.  Molecularly targeted therapies for p53-mutant cancers , 2017, Cellular and Molecular Life Sciences.

[9]  T. Komori,et al.  The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision , 2017, Neurologia medico-chirurgica.

[10]  K. Saikia,et al.  Point mutations in the DNA binding domain of p53 contribute to glioma progression and poor prognosis , 2017, Molecular Biology.

[11]  Ning Liu,et al.  BACH1 Promotes Temozolomide Resistance in Glioblastoma through Antagonizing the Function of p53 , 2016, Scientific Reports.

[12]  Y. Mao,et al.  TP53 and Histone H3.3 Mutations in Triple-Negative Lower-Grade Gliomas. , 2016, The New England journal of medicine.

[13]  T. Hortobágyi,et al.  Immunohistochemical correlates of TP53 somatic mutations in cancer , 2016, Oncotarget.

[14]  Dmitriy Sonkin,et al.  TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data , 2016, Human mutation.

[15]  Satoshi O. Suzuki,et al.  Precise Detection of IDH1/2 and BRAF Hotspot Mutations in Clinical Glioma Tissues by a Differential Calculus Analysis of High-Resolution Melting Data , 2016, PloS one.

[16]  Lanbing Yu,et al.  Analysis of Treatment Tolerance and Factors Associated with Overall Survival in Elderly Patients with Glioblastoma. , 2016, World neurosurgery.

[17]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[18]  K. Ichimura,et al.  Revisiting TP53 Mutations and Immunohistochemistry—A Comparative Study in 157 Diffuse Gliomas , 2015, Brain pathology.

[19]  Yanhui Liu,et al.  Gain of Function of Mutant TP53 in Glioblastoma: Prognosis and Response to Temozolomide , 2014, Annals of Surgical Oncology.

[20]  Karen H. Vousden,et al.  Mutant p53 in Cancer: New Functions and Therapeutic Opportunities , 2014, Cancer cell.

[21]  L. Salnikova.  Clinicopathologic Characteristics of Brain Tumors are Associated with the Presence and Patterns of TP53 Mutations: Evidence from the IARC TP53 Database , 2014, NeuroMolecular Medicine.

[22]  M. Schlaak,et al.  Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations , 2014, BMC Cancer.

[23]  Yanhui Liu,et al.  Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O6-methylguanine DNA-methyltransferase , 2013, Neurological Sciences.

[24]  Emily Zeringer,et al.  Improving the limit of detection for Sanger sequencing: A comparison of methodologies for KRAS variant detection. , 2012, BioTechniques.

[25]  P. Kleihues,et al.  Genetic profile of astrocytic and oligodendroglial gliomas , 2011, Brain Tumor Pathology.

[26]  J. Khan,et al.  Detection of Somatic Mutations by High-Resolution DNA Melting (HRM) Analysis in Multiple Cancers , 2011, PloS one.

[27]  D. Petersen,et al.  Assessing high‐resolution melt curve analysis for accurate detection of gene variants in complex DNA fragments , 2009, Human mutation.

[28]  S. Fox,et al.  High resolution melting for mutation scanning of TP53 exons 5–8 , 2007, BMC Cancer.

[29]  M. Weller,et al.  O6‐methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells , 2006, Journal of neurochemistry.

[30]  S. Duensing,et al.  Guilt by association? p53 and the development of aneuploidy in cancer. , 2005, Biochemical and biophysical research communications.

[31]  S. Kato,et al.  Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations , 2005, Human mutation.

[32]  N. Probst-Hensch,et al.  Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas , 2004, Acta Neuropathologica.

[33]  P. Kleihues,et al.  Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  Douglas C. Miller,et al.  A Correlative Study of p53 Protein Alteration and p53 Gene Mutation in Glioblastoma Multiforme , 1993, Brain pathology.

[35]  D. Louis.  WHO classification of tumours of the central nervous system , 2007 .